Assembly Biosciences, Inc.
ASMB
NASDAQ·Healthcare·Biotechnology·Mkt cap $725.3M
$36.60
▲ +1.30%
P/E
66.55
Mkt Cap
$725.3M
52-Wk Range
$20.23–$39.71
52-Week Range
$20.23 - $39.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 57.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced clinical-stage HBV drug candidates with Phase 2 data
- Strategic partnerships with leading biotech and pharmaceutical companies
- Specialized expertise in hepatitis B virus treatment discovery
- Multiple product candidates addressing different treatment approaches
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Advancement of Vebicorvir through Phase 3 clinical trials
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+62.2% over 3m
Quality
Excellent
High-growth business (121% revenue growth, 78% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying ASMB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 13, 2026
Reported EPS of -$0.20 vs -$0.72 consensus (+72.4% surprise). Revenue of $13.4M vs $8.6M expected (+55.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+72.4%
Revenue trend · last 8Q
—
—
+63%
+13%
+58%
+477%
-13%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$6.8M
$7.4M
$9.4M
$9.6M
$10.8M
$42.5M
$8.2M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · May 28, 2026
vs Industry
How ASMB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related